Cooley advised CymaBay, and Paul Hastings advised the representatives of the underwriters.CymaBay Therapeutics, Inc. announced its $258.75 million follow-on offering of common stock and pre-funded warrants,…
Standard 1 Year Membership Required
You must be a Standard 1 Year member to access this content.
Already a member? Log in here
